Uveal melanoma is the most common primary malignancy of the eye and frequently leads to metastatic death. Until the mid-20th Century, the only treatment for uveal melanoma was enucleation.

Study findings show that the standardized 6-month surveillance protocols for all patients with low-risk uveal melanoma may be ...

The objectives of ocular treatment are to prevent metastatic spread, and if possible, to conserve the eye and useful vision. Eye-conserving therapeutic modalities include various forms of ...

The summer of 2023 saw the approval of a new treatment option for certain patients with uveal melanoma, a form of cancer that begins in the eye and remains a challenge to treat. Richard Staines ...

Patient-derived organoids can be established from uveal melanoma tumors. Credit: Investigative Ophthalmology & Visual Science ...

This disease, known as metastatic uveal melanoma, is traditionally very hard to treat and usually has poor outcomes. The objective response rate was 27.5%, nearly three times the 9.4% observed in ...

You may have treatment with radiotherapy if you have melanoma of the eye (uveal melanoma). These treatments can work well, but some people have a small number of cancer cells left at the end of ...

HealthDay News — For patients with unresectable metastatic uveal melanoma (mUM), the drug/device combination melphalan/hepatic delivery system (HDS) is efficacious and has a favorable risk-benefit ...

Castle Biosciences, Inc. announced that it will present new research at the AACR Annual Meeting 2025 aimed at improving the care of patients with cutaneous and uveal melanoma. The presentations ...

The study, titled “An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma,” indicates that ...

has announced the progression of its Phase 3 clinical trial for darovasertib as a neoadjuvant therapy for primary uveal melanoma (UM), following a successful FDA Type D meeting. According to ...